BillionToOne, Inc. (BLLN)
Nasdaq: BLLN · Services-Medical Laboratories · Menlo Park, CA · filing with the SEC since 2025
Who owns BillionToOne, Inc.
As filed with the SECHolders of 5% or more
4
Hummingbird Ventures Management NV holds 19.6% of Class A common stock, as its SCHEDULE 13D filed Jan 20, 2026 says.
Directors and officers
13
report now, of 13 people on the record since 2025. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Hummingbird Ventures Management NV
SCHEDULE 13D · filed Jan 20, 2026 · Class A common stock
Krishna Kittu Kolluri ("Kolluri")
SCHEDULE 13G · filed Feb 13, 2026 · Class A Common Stock, par value $0.00001 per share
Oguzhan Atay
SCHEDULE 13G · filed Feb 17, 2026 · Class A common stock, par value $0.00001 per share
David Tsao
SCHEDULE 13G · filed Feb 17, 2026 · Class A common stock, par value $0.00001 per share
What BLLN reports owning in othersstakes of 5% or more, and other ties
BillionToOne, Inc. reports no stake in another company in the record.
Insider tradesForm 4
213sales
0purchases
213sales on a scheduled plan
6people selling
$58.5Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 28 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Atay Oguzhan | Chairman and CEO | 108 | $30.5M | 108 | 0 | $0 |
| Tsao David | Chief Technology Officer | 51 | $13.2M | 51 | 0 | $0 |
| Lynch Thomas P. | See Remarks | 17 | $5.9M | 17 | 0 | $0 |
| Johnson Nancy Joann | Senior Vice President of Sales and Commercial Operations | 12 | $3.3M | 12 | 0 | $0 |
| Sakakibara Shan Riku | Chief Product Officer | 10 | $3.2M | 10 | 0 | $0 |
| Ten Bosch John Roderick | SVP of Laboratory Operations | 15 | $2.3M | 15 | 0 | $0 |